York Capital and Enovix

In June 2020, Jeremy Blank prepared for a meeting with his fellow partners at York Capital to discuss an investment he had championed in Enovix, a company developing a state-of-the-art, silicon-based battery. Early-stage technology companies, like Enovix, were not typical investments for York, but Blank had convinced his partners to invest. However, the partnership wanted to be “one and done” without reinvesting in future rounds. By 2020, Enovix had made great progress but not as quickly as forecasted. The company had set out to raise more money and received a term sheet from a well-known publicly-traded company. Blank saw this as an exciting opportunity for Enovix, but he was disappointed to see that it would require York to invest more capital and forego a key protective feature. How should Blank approach this meeting with his partners, and what should he recommend?